MicroRNA expression Aberration as potential peripheral blood biomarkers for Schizophrenia

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Lai, Chi Yu ^a   Yu, Sung Liang ^a,b   Hsieh, Ming H ^c   Chen, Chun Houh ^d   Chen, Hsuan Yu ^a,d   Wen, Chun Chiang ^c   Huang, Yung Hsiang ^a   Hsiao, Po Chang ^a   Hsiao, Chuhsing Kate ^a   Liu, Chih Min ^c   Yang, Pan Chyr ^a,c   Hwu, Hai Gwo ^a,c   Chen, Wei J ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 34A; MICRORNA 432; MICRORNA 449A; MICRORNA 548D; MICRORNA 564; MICRORNA 572; MICRORNA 652; RNA; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC IDENTIFICATION; GENETIC MARKER; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MENTAL PERFORMANCE; MONONUCLEAR CELL; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; SCHIZOPHRENIA; VALIDATION PROCESS; BLOOD; CASE CONTROL STUDY;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; MICRORNAS; SCHIZOPHRENIA;

EID: 79959663462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021635     Document Type: Article

References (73)

1. Tamminga CA, Holcomb HH, (2005) Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10: 27-39.
2. Joyce EM, Roiser JP, (2007) Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 20: 268-272.
3. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, et al. (2007) Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33: 69-94.
4. van Os J, Kenis G, Rutten BPF, (2010) The environment and schizophrenia. Nature 468: 203-212.
5. Harrison PJ, Weinberger DR, (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68.
6. Gottesman II, Gould TD, (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645.
7. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA, (2008) Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res 106: 89-107.
8. Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, et al. (2006) Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 24: 942-946.
9. Schwarz E, Bahn S, (2008) The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol 153 (Suppl 1): S133-136.
10. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, et al. (2004) Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67: 41-52.
11. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, et al. (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci USA 102: 15533-15538.
12. Sullivan PF, Fan C, Perou CM, (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141: 261-268.
13. Kuzman MR, Medved V, Terzic J, Krainc D, (2009) Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. J Psychiatr Res 43: 1073-1077.
14. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, et al. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40: 827-834.
15. Gladkevich A, Kauffman HF, Korf J, (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 559-576.
16. Marques-Deak A, Cizza G, Sternberg E, (2005) Brain-immune interactions and disease susceptibility. Mol Psychiatry 10: 239-250.
17. Marazziti D, Catena Dell'Osso M, Baroni S, Masala I, Dell'Osso B, et al. (2010) Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. Psychiatry Res 175: 54-57.
18. Liu L, Jia F, Yuan G, Chen Z, Yao J, et al. (2010) Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 176: 1-7.
19. Yao Y, Schroder J, Karlsson H, (2008) Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia. J Psychiatr Res 42: 639-643.
20. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
21. Perkins DO, Jeffries C, Sullivan P, (2005) Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. Mol Psychiatry 10: 69-78.
22. Cheng H-YM, Papp JW, Varlamova O, Dziema H, Russell B, et al. (2007) microRNA modulation of circadian-clock period and entrainment. Neuron 54: 813-829.
23. Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, Ramsey AJ, et al. (2009) MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci USA 106: 3507-3512.
24. Coyle JT, (2009) MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proc Natl Acad Sci USA 106: 2975-2976.
25. Miller BH, Wahlestedt C, (2010) MicroRNA dysregulation in psychiatric disease. Brain Res 1338: 89-99.
26. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, et al. (2007) microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8: R27.
27. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, et al. (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17: 1156-1168.
28. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ, (2010) Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15: 1176-1189.
29. Hassan SS, Romero R, Pineles B, Tarca AL, Montenegro D, et al. (2010) MicroRNA expression profiling of the human uterine cervix after term labor and delivery. Am J Obstet Gynecol 202: 80 e81-88.
30. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, et al. (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36: D165-169.
31. Wheeler G, Ntounia-Fousara S, Granda B, Rathjen T, Dalmay T, (2006) Identification of new central nervous system specific mouse microRNAs. FEBS Lett 580: 2195-2200.
32. Guyon I, Weston J, Barnhill S, Vapnik V, (2002) Gene selection for cancer classification using support vector machines. Mach Learn 46: 389-422.
33. Kay SR, (1991) Positive and Negative Syndromes in Schizophrenia: Assessment and Research New York Brunner/Mazel.
34. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, et al. (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 155: 1214-1220.
35. Chen WJ, Hsiao CK, Hsiao LL, Hwu HG, (1998) Performance of the Continuous Performance Test among community samples. Schizophr Bull 24: 163-174.
36. Lin CCH, Chen WJ, Yang H-J, Hsiao CK, Tien AY, (2000) Performance on the Wisconsin Card Sorting Test among adolescents in Taiwan: Norms, factorial structure, and relation to schizotypy. J Clin Exp Neuropsychol 22: 69-79.
37. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, et al. (1996) Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch Gen Psychiatry 53: 1114-1121.
38. Light GA, Braff DL, (2005) Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62: 127-136.
39. MAMI-Meta prediction of microRNA targets: < http://mami.med.harvard.edu/>.
40. Sethupathy P, Megraw M, Hatzigeorgiou AG, (2006) A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 3: 881-886.
41. Jasinska AJ, Service S, Choi OW, DeYoung J, Grujic O, et al. (2009) Identification of brain transcriptional variation reproduced in peripheral blood: an approach for mapping brain expression traits. Hum Mol Genet 18: 4415-4427.
42. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, et al. (2005) Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133: 1-5.
43. van Heerden JH, Conesa A, Stein DJ, Montaner D, Russell V, et al. (2009) Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse. BMC Res Notes 2: 195.
44. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, et al. (2010) MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 124: 183-191.
45. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, et al. (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34: 1395-1405.
46. Shibata H, Tani A, Chikuhara T, Kikuta R, Sakai M, et al. (2009) Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res 167: 88-96.
47. Schipper HM, Maes OC, Chertkow HM, Wang E, (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 1: 263-274.
48. Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, et al. (2008) Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 9: 153-161.
49. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, et al. (2008) Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14: 27-41.
50. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37: D105-110.
51. Cheung ZH, Fu AK, Ip NY, (2006) Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron 50: 13-18.
52. Glatt SJ, Faraone SV, Lasky-Su JA, Kanazawa T, Hwu HG, et al. (2009) Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan. Mol Psychiatry 14: 885-893.
53. Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, et al. (2010) Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res 120: 150-158.
54. Hoh NZ, Wagner AK, Alexander SA, Clark RB, Beers SR, et al. (2010) BCL2 genotypes: functional and neurobehavioral outcomes after severe traumatic brain injury. J Neurotrauma 27: 1413-1427.
55. Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, et al. (2009) Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 12: 1337-1354.
56. Lize M, Pilarski S, Dobbelstein M, (2009) E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 17: 452-458.
57. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders Washington, DC American Psychiatric Association.
58. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, et al. (1994) Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849-859.
59. Chang C-J, Chen WJ, Liu S-K, Cheng JJ, Ou Yang W-C, et al. (2002) Morbidity risk of psychiatric disorders among the first degree relatives of schizophrenia patients in Taiwan. Schizophr Bull 28: 379-392.
60. Cheng JJ, Ho H, Chang CJ, Lan SY, Hwu HG, (1996) Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Chinese Psychiatry 10: 251-258.
61. Liu SK, Hwu HG, Chen WJ, (1997) Clinical symptom dimensions and deficits on the Continuous Performance Test in schizophrenia. Schizophr Res 25: 211-219.
62. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G, (1993) Wisconsin Card Sorting Test Manual: Revised and Expanded: Psychological Assessment Resources Odessa, FL.
63. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
64. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, et al. (2008) Real-time PCR quantification of precursor and mature microRNA. Methods 44: 31-38.
65. Simon R, Radmacher MD, Dobbin K, McShane LM, (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18.
66. Miettinen OS, (1976) Stratification by a multivariate confounder score. Am J Epidemiol 104: 609-620.
67. Wu HM, Tien YJ, Chen C, (2010) GAP: A graphical environment for matrix visualization and cluster analysis. Comput Stat Data Anal 54: 767-778.
68. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, et al. (2004) A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18: 1165-1178.
69. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
70. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
71. Wang X, (2006) Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res 34: 1646-1652.
72. Betel D, Wilson M, Gabow A, Marks DS, Sander C, (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153.
73. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc Ser B57: 289-300.